ECSP14024494A - Antibodies to Bradykinin B1 Receptor Ligands - Google Patents

Antibodies to Bradykinin B1 Receptor Ligands

Info

Publication number
ECSP14024494A
ECSP14024494A ECIEPI201424494A ECPI201424494A ECSP14024494A EC SP14024494 A ECSP14024494 A EC SP14024494A EC IEPI201424494 A ECIEPI201424494 A EC IEPI201424494A EC PI201424494 A ECPI201424494 A EC PI201424494A EC SP14024494 A ECSP14024494 A EC SP14024494A
Authority
EC
Ecuador
Prior art keywords
kallidin
antibodies
des
arg10
bradykinin
Prior art date
Application number
ECIEPI201424494A
Other languages
Spanish (es)
Inventor
Matthew Davidson
Xin Chen
Han Li
Jie Zhang
Alla Pritsker
Nicolas Baurin
Govindan Subramanian
Dorothea KOMINOS
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP14024494A publication Critical patent/ECSP14024494A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Resumen: La invención proporciona anticuerpos que se unen específicamente a calidina o des-Arg10-calidina. La invención proporciona también composiciones farmacéuticas, así como ácido nucleicos que codifican anticuerpos anti-calidina o anti des-Arg10-calidina, vectores de expresión recombinantes y células hospedantes para producir dichos anticuerpos, o fragmentos de los mismos. También son proporcionados por la invención métodos de uso de los anticuerpos de la invención para modular la actividad de la calidina o des-Arg10-calidina o para detectar la calidina o la des-Arg10-calidina, ya sea in vitro o in vivo. La invención proporciona además métodos para producir anticuerpos que se unen específicamente a des-Arg9- bradicinina y a un péptido tipo des-Arg10-calidina.Summary: The invention provides antibodies that specifically bind to kallidin or des-Arg10-kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-kallidin or anti-des-Arg10-kallidin antibodies, recombinant expression vectors and host cells to produce said antibodies, or fragments thereof. Also provided by the invention are methods of using the antibodies of the invention to modulate the activity of kallidin or des-Arg10-kallidin or to detect kallidin or des-Arg10-kallidin, either in vitro or in vivo. The invention further provides methods for producing antibodies that specifically bind des-Arg9-bradykinin and a des-Arg10-kallidin-like peptide.

ECIEPI201424494A 2012-03-28 2014-10-27 Antibodies to Bradykinin B1 Receptor Ligands ECSP14024494A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04

Publications (1)

Publication Number Publication Date
ECSP14024494A true ECSP14024494A (en) 2015-09-30

Family

ID=73005822

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201424494A ECSP14024494A (en) 2012-03-28 2014-10-27 Antibodies to Bradykinin B1 Receptor Ligands

Country Status (1)

Country Link
EC (1) ECSP14024494A (en)

Similar Documents

Publication Publication Date Title
DOP2014000199A (en) ANTIBODIES AGAINST BRADICININE B1 RECEIVER LIGANDS
CR20160117A (en) ANTIBODIES AGAINST THE TYPE 1 (PAI-1) PLASMINOGEN ACTIVATOR INHIBITOR AND USES OF THE SAME
CY1122676T1 (en) ANTIBODIES TO CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS
PE20180672A1 (en) ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE OF THE SAME
UY32971A (en) PROTEINS OF UNION TO THE ANTIGEN OF HUMAN IL-23
EA201592269A1 (en) METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS
ECSP15025845A (en) ANTI-CEACAM5 ANTIBODIES AND USES OF THEM
EA201691078A1 (en) THERAPEUTIC PEPTIDES
MY175708A (en) Dna antibody constructs and method of using same
UY34885A (en) ANTI-MESOTHELINE UNION PROTEINS
EA201991409A2 (en) ANTIBODIES TO PLASMINOGEN 1 (PAI-1) ACTIVATOR INHIBITOR AND WAYS OF THEIR APPLICATION
BR112014002817A2 (en) Use of a p62 polypeptide, or a nucleic acid encoding p62
ECSP14013132A (en) ANTI-PSGL-1 ANTIBODIES AND USES OF THE SAME
PE20160528A1 (en) ANTIBODIES
CO6680702A2 (en) Peptide or peptide complex that binds to integrin alpha 2 and methods and their uses that involve them
AR080680A1 (en) BASIGIN UNION PROTEINS
TR201910413T4 (en) Methods for improving asthma symptoms using benralizumab.
EA201390955A1 (en) ROBO1-FC fusion protein for use in the treatment of hepatocarcinoma
MX2016004754A (en) Novel four-ctl epitope-joined peptide.
ECSP14024494A (en) Antibodies to Bradykinin B1 Receptor Ligands
PH12014502182A1 (en) Methods and compositions for modulating notch activity
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
EA201792665A1 (en) ANTIBODIES AGAINST CTLA-4 AND METHODS OF THEIR APPLICATION
AR101757A1 (en) ANTI-MFI2 ANTIBODIES AND METHODS OF USE
AR103294A1 (en) COMPOSITIONS AND PROCEDURES FOR THE GLYCOSILATION OF PROTEINS